The explosive demand for Ozempic and Wegovy during the GLP-1 medication boom created supply shortages that spawned an entire industry of compounded semaglutide â versions of the drug produced by compounding pharmacies rather than manufactured by Novo Nordisk. At their peak, hundreds of telehealth companies were prescribing and dispensing compounded semaglutide injections at fractions of the brand-name cost, often with minimal medical oversight. The FDA issued multiple warnings about compounded semaglutide, citing contamination risks, salt form discrepancies, and lack of manufacturing oversight. For patients with SIBO or gut motility issues, the unpredictable pharmacology of compounded versions adds additional layers of risk. This article covers what compounded semaglutide is, why it carries unique gut health concerns, and how to evaluate your risk if you're currently using a compounded product.
What Is Compounded Semaglutide?
Compounding pharmacies are licensed facilities that can prepare customized medications for patients with specific needs â a valid and often essential service for patients who need different doses, formulations, or delivery mechanisms than commercially available products provide. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies have the authority to prepare medications, including versions of FDA-approved drugs, under certain conditions. During a drug shortage, 503B outsourcing facilities can compound copies of shortage drugs. When semaglutide appeared on the FDA drug shortage list between 2022 and 2024, hundreds of compounding facilities began producing semaglutide injections for distribution through telehealth companies.
The compounded products are structurally and chemically different from branded Ozempic and Wegovy in ways that matter. FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus) uses semaglutide base as the active ingredient. The majority of compounded semaglutide uses semaglutide sodium or semaglutide acetate â salt forms of the molecule. The FDA has explicitly stated that the safety and effectiveness of these salt forms has not been demonstrated, because the clinical trials establishing semaglutide's efficacy and safety profile were conducted exclusively with semaglutide base.
â ī¸FDA Warning (2024): The FDA has stated that compounded semaglutide products using semaglutide sodium or acetate are not FDA-approved and their safety profiles have not been established. These are not the same product as Ozempic or Wegovy, despite containing a semaglutide salt. The agency has documented adverse event reports from compounded semaglutide users including hospitalization.
Salt Form Differences: Sodium vs. Acetate vs. Base
The distinction between semaglutide base, semaglutide sodium, and semaglutide acetate is chemically meaningful, not a trivial labeling difference. Salt forms of peptide drugs can differ in solubility, stability, bioavailability, and release kinetics. A medication formulated as the sodium salt may behave differently in subcutaneous tissue than the base compound â it could be absorbed faster, slower, or differently, producing a different pharmacokinetic curve even if the total mass administered is equivalent.
For gut health, this matters because semaglutide's GI effects â gastric emptying delay, MMC suppression, nausea â are dose- and concentration-dependent. If a salt form is absorbed more rapidly than the base compound, peak plasma concentrations may be higher, potentially producing more severe acute gut effects. If absorption is more erratic (as can occur with poorly formulated peptide injections), patients may experience unpredictable waves of gut suppression and recovery rather than the steady-state motility effect that occurs with properly formulated branded semaglutide. For SIBO patients, this unpredictability makes managing the gut effects far more difficult.
Dosing Inconsistencies and Contamination Risks
Unlike pharmaceutical manufacturers who operate under Current Good Manufacturing Practices (cGMP) with validated analytical testing of every production batch, compounding pharmacies operate under different oversight frameworks. Quality and potency testing requirements for compounded products vary significantly between states and between 503A (patient-specific) and 503B (outsourcing facility) pharmacies. The FDA's inspection of compounding pharmacies has found significant variability in product potency â meaning the amount of semaglutide (in any salt form) in a vial can differ substantially from the labeled dose.
The agency's adverse event database received hundreds of reports from compounded semaglutide users between 2022 and 2024, including cases of severe nausea and vomiting requiring hospitalization, hypoglycemia at doses not associated with hypoglycemia in branded semaglutide users (raising questions about potency or contaminants), and injection site reactions suggesting formulation or sterility issues. Several compounding facilities have issued voluntary recalls after contamination or potency failures were discovered. The FDA has documented cases where vials labeled as containing a specific dose of semaglutide contained significantly more or less than stated.
âšī¸For gut health specifically, dosing inconsistency in compounded semaglutide is particularly problematic. If one week's injection delivers 50% more semaglutide than labeled, the gastric emptying suppression will be correspondingly greater â potentially triggering severe gut stasis, nausea, and the conditions for acute bacterial overgrowth. The next week's 50% lower-than-expected dose creates an entirely different motility state. This variability makes symptoms nearly impossible to manage predictably.
Unpredictable Gut Side Effects: What Patients Report
Patient communities online document a consistent pattern with compounded semaglutide that differs from the branded product experience. Users report more erratic GI symptoms â severe nausea one week that is absent the next, unpredictable constipation patterns, and in some cases, more abrupt gastrointestinal effects immediately after injection. This pattern is consistent with the pharmacokinetic inconsistency expected from variable-potency compounded products.
For SIBO patients, the practical consequence is that the gut-slowing effects of compounded semaglutide are less predictable and therefore harder to manage. With branded Ozempic or Wegovy, patients can reasonably anticipate their gut response at each dose level after stabilizing, allowing them to optimize meal timing, prokinetic use, and dietary choices accordingly. With compounded semaglutide, the pharmacology is a moving target â making evidence-based gut management strategies far less reliable.
How to Evaluate a Compounding Pharmacy
Questions to Ask Before Using Compounded Semaglutide
- Is the pharmacy a 503B outsourcing facility? 503B facilities operate under stricter oversight than 503A pharmacies and must register with the FDA. Ask for the pharmacy's 503B registration number.
- What salt form is used? Ask specifically whether the product uses semaglutide base, semaglutide sodium, or semaglutide acetate. If they cannot or will not answer, that is a significant red flag.
- Is potency testing performed on each batch? Reputable 503B pharmacies perform certificate of analysis (COA) testing on each production batch. Ask to see the COA for your specific lot number.
- Has the pharmacy had recent FDA inspections or warning letters? Check the FDA's 503B outsourcing facility list and warning letter database at fda.gov before using any compounding pharmacy.
- What is the sterility testing protocol? Injectable compounded products should have sterility testing. Ask for documentation.
- Is the prescriber reviewing your progress? Compounded semaglutide distributed through telehealth with no clinical follow-up or dose adjustment represents the highest-risk use pattern. Ensure you have a prescriber who can monitor and adjust your treatment.
The Path Forward: Transitioning to Branded Products
As Ozempic and Wegovy supply has normalized and the FDA has removed semaglutide from its shortage list, the regulatory basis for most compounded semaglutide has been eliminated. The FDA has announced that after a transition period, 503A and 503B pharmacies may no longer legally compound copies of semaglutide products for routine prescribing. Patients currently on compounded semaglutide who are experiencing significant gut side effects should discuss transitioning to the branded product with their prescriber.
The transition itself requires care for SIBO patients. Moving from an inconsistently dosed compounded product to a precisely dosed branded product may change the gut motility effects â potentially for better or worse depending on what dose you were actually receiving. A conservative approach is to start the branded product at a lower dose than your compounded dose and titrate up, monitoring gut symptoms carefully. If SIBO symptoms have developed during compounded semaglutide use, obtain a breath test before or shortly after transitioning to establish your current bacterial overgrowth status.
**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.